Is Brilinta in shortage in 2026? Get the latest update on Brilinta and Ticagrelor availability, pricing, generic options, and how to find it in stock.
If you take Brilinta (Ticagrelor) for your heart condition, you may have heard rumors about shortages or experienced difficulty finding it at your pharmacy. So what's actually going on with Brilinta availability in 2026?
Here's the short answer: Brilinta is not currently listed on the FDA's official drug shortage database. However, that doesn't mean every pharmacy has it on the shelf. The reality is more nuanced — and understanding the current landscape can help you avoid gaps in your treatment.
As of early 2026, Brilinta (brand name) and generic Ticagrelor are not in a formal FDA-listed shortage. This is good news. Unlike some other cardiovascular medications that have faced severe supply disruptions, the Brilinta supply chain is generally intact.
However, patients are still reporting difficulty finding the medication at certain pharmacies. Why? The answer lies in the generic transition that began in mid-2025 and the ripple effects it has created across the pharmacy landscape.
Even without a formal shortage, several factors can make Brilinta difficult to find at your local pharmacy:
When generic Ticagrelor launched in mid-2025, the pharmaceutical supply chain went through a major shift. Multiple manufacturers — including Alembic, Novadoz, Ascend, Teva, and Hisun Pharmaceuticals — began producing generic versions. This led to:
Chain pharmacies use automated systems to manage inventory. If a location doesn't fill many Ticagrelor prescriptions, the algorithm may keep little or no stock. This is particularly common in areas with fewer cardiac patients.
Some insurance plans have been slow to update their formularies to include all generic Ticagrelor manufacturers. Others still require prior authorization or step therapy (trying Clopidogrel first), which creates delays even when the pharmacy has the medication available. For more on this, read why Brilinta is hard to find in 2026.
The cost picture for Brilinta has changed significantly with the arrival of generics:
One important change for 2026: AstraZeneca removed Brilinta from its AZ&Me patient assistance program effective January 1, 2026. Patients who previously relied on this free medication program will need to explore other options. For a complete guide to savings, see how to save money on Brilinta.
The arrival of generic Ticagrelor is the biggest development for Brilinta patients in years. Here's what it means for you:
With at least five generic manufacturers now producing Ticagrelor, the overall supply of this medication is actually better than ever. Even if one manufacturer has a production issue, others can fill the gap.
Generic competition has driven prices down dramatically. If you've been paying hundreds of dollars per month for brand Brilinta, switching to generic Ticagrelor could save you $400 or more per month.
As the generic market matures, more pharmacies — including mail-order and online pharmacies — are stocking Ticagrelor. This gives you more places to fill your prescription.
If your pharmacy doesn't have Brilinta or Ticagrelor, here's what to do:
For more detailed tips, read our guide on how to find Brilinta in stock near you.
While Brilinta is not in a formal shortage in 2026, the generic transition and pharmacy stocking decisions can still make it tricky to find. The silver lining is that generic Ticagrelor has made this medication more affordable and more widely available than ever before.
Stay proactive about your refills, use tools like Medfinder to check availability, and talk to your doctor if you're having trouble. Your heart health depends on taking Brilinta consistently — and with the right approach, you can make sure you never miss a dose.
Want to learn more about Brilinta? Check out our guides on Brilinta side effects and Brilinta drug interactions.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
